An online survey of hypothyroid patients demonstrates prominent dissatisfaction by Peterson, Sarah J. et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/117488/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Peterson, Sarah J., Cappola, Anne R., Castro, M. Regina, Dayan, Colin M., Farwell, Alan P.,
Hennessey, James V., Kopp, Peter A., Ross, Douglas S., Samuels, Mary H., Sawka, Anna M.,
Taylor, Peter N., Jonklaas, Jacqueline and Bianco, Antonio C. 2018. An online survey of
hypothyroid patients demonstrates prominent dissatisfaction. Thyroid 28 (6) , p. 707.
10.1089/thy.2017.0681 file 
Publishers page: http://dx.doi.org/10.1089/thy.2017.0681 <http://dx.doi.org/10.1089/thy.2017.0681>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
1 
 
Exploring dissatisfaction with treatment of hypothyroidism:  1 
coexistent diseases and treatment preferences 2 
 3 
Sarah J. Peterson1, Anne R. Cappola2, M. Regina Castro3 Colin M. Dayan4, Alan P. Farwell5, 4 
James V. Hennessey6, Peter A. Kopp7, Douglas S. Ross8, Mary H. Samuels9, Anna M. Sawka10, 5 
Peter N. Taylor4, Jacqueline Jonklaas11, Antonio C. Bianco1 6 
 7 
1Division of Endocrinology and Metabolism, Rush University Medical Center, Chicago, Illinois, 8 
USA 9 
2Division of Endocrinology, Mayo Clinic, Rochester, MN, USA 10 
3Division of Endocrinology, Diabetes, and Metabolism, Perelman School of Medicine, Universi-11 
ty of Pennsylvania, Philadelphia, PA, USA 12 
4Division of Diabetes and Metabolism, Cardiff University, Cardiff, Wales, UK  13 
5School of Medicine, Boston University, Boston, MA, USA 14 
6Division of Endocrinology, Beth Israel Deaconess Medical Center, Boston, MA, USA 15 
7Feinberg School of Medicine, Northwestern University, Chicago, IL, USA 16 
8Thyroid Associates, Massachusetts General Hospital, Boston, MA, USA 17 
9Oregon Clinical and Translational Research Institute, Oregon Health & Science University, 18 
Portland, OR, USA 19 
10University Health Network and University of Toronto, Toronto, Ontario, Canada 20 
11Division of Endocrinology, Georgetown University, Washington, District of Columbia, USA 21 
 22 
Key terms: levothyroxine, hypothyroidism, TSH, combination therapy, T3, desiccated thyroid 23 
extract 24 
Word count:  25 
Number of figures and tables: 5 26 
Corresponding authors and person to whom reprint requests should be addressed: 27 
Antonio C. Bianco, M.D., Ph.D. 28 
Division of Endocrinology and Metabolism 29 
Rush University Medical Center 30 
1735 W Harrison St; Cohn Building Rm 212; Chicago, IL 60612 31 
Email: abianco@deiodinase.org; Phone: 312-942-7131; Fax: 312-942-5271 32 
 33 
Jacqueline Jonklaas M.D 34 
Division of Endocrinology, Georgetown University  35 
4000 Reservoir Road, NW; Bldg. D Suite 230, Washington, DC 20007 36 
Email: jonklaaj@georgetown.edu; Phone: 202-687-2818; Fax: 877-485-1479 37 
 38 
  39 
2 
 
ABSTRACT 40 
 41 
 42 
Context: Levothyroxine (LT4) monotherapy is the standard of care for treating hypothyroidism. 43 
However, some patients do not feel well and express interest in other therapies. 44 
Objective: To inform the discussion at a symposium addressing treatment for hypothyroidism, 45 
we wished to determine perceptions of patients regarding their treatment for hypothyroidism. 46 
Design: An online survey was created to obtain patient’s perceptions. Respondents were asked to 47 
rank satisfaction with their treatment for hypothyroidism, satisfaction with their treating physi-48 
cian, perceived physician knowledge about hypothyroidism treatments, perceived need for new 49 
treatments for hypothyroidism, and perceived life impact of hypothyroidism on a scale of 1 to 50 
10. Respondents were asked to report the type of thyroid hormone they were taking, which was 51 
categorized as LT4, LT4 and liothyronine (LT4 + LT3), or desiccated thyroid extract (DTE). 52 
They also reported sex, age, cause of hypothyroidism, duration of treatment, medical history, and 53 
prevalence of symptoms or side effects. 54 
Participants: A convenience sample of survey respondents with self-reported hypothyroidism. 55 
Results: A total of 12,146 individuals completed the survey. Among respondents without self-56 
reported depression, stressors or medical conditions (n=3670), individuals taking DTE reported a 57 
higher median treatment satisfaction of 7 (interquartile range (IQR): 5,9) and a higher physician 58 
satisfaction of 7 (IQR: 4,9) compared to other treatments. For LT4 treatment, satisfaction was 5 59 
(IQR: 3,7) and physician dissatisfaction was 6 (IQR: 3,8). For LT4 + LT3 treatment, satisfaction 60 
was 6 (IQR: 3,8) and physician satisfaction was 6 (IQR: 3,8). Respondents taking DTE were also 61 
less likely to report hypothyroidism-associated side effects related to weight management, fa-62 
tigue/energy levels, mood, and memory/other cognitive problems, compared to those taking LT4 63 
or LT4 + LT3. The study design does not permit investigation of why patients taking DTE re-64 
ported best perceived outcomes. 65 
Conclusions: Despite the limitations of the study and the potential for sampling bias, data from 66 
this large convenience sample of hypothyroid individuals revealed generalized dissatisfaction 67 
with treatment and physicians; patients taking DTE reported best perceived outcomes. Future 68 
studies into what constitutes euthyroidism and what determines satisfaction with therapy are 69 
needed. 70 
 71 
 72 
  73 
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 74 
INTRODUCTION 75 
 76 
Hypothyroidism is a common endocrine problem that results from insufficient secretion of thy-77 
roid hormones due to an underactive thyroid gland; it requires lifelong treatment with thyroid 78 
hormone replacement therapy.1 Currently, the standard of care to treat hypothyroidism is daily 79 
administration of levothyroxine (LT4), at doses that normalize serum thyroid stimulating hor-80 
mone (TSH).2,3 Even though thyroxine (T4) is intrinsically active in some settings4, many tissues 81 
have deiodinases that activate T4 to triiodothyronine (T3), the biologically active thyroid hor-82 
mone. The prevailing viewpoint is that a dosage of LT4 that normalizes serum TSH also normal-83 
izes serum and tissue T3 levels.5  Endocrinologists’ offices are frequently visited by hypothyroid 84 
patients that remain symptomatic despite being “appropriately” treated, complaining of sluggish-85 
ness, lethargy, sleepiness, memory problems, depression, cold intolerance, hoarseness, dry skin, 86 
body weight gain, and constipation.1 Anecdotally, we know that these patients switch physician 87 
multiple times and many use unconventional therapies, such as dietary supplements, nutraceuti-88 
cals and over-the-counter products.  89 
 90 
Most patients with hypothyroidism experience resolution of their symptoms with standard thera-91 
py. However, 10 to 15% more of LT4-treated patients have poor quality of life compared with 92 
control individuals.6  The existence of patients with hypothyroidism who are symptomatic de-93 
spite LT4 treatment that has normalized their TSH values has lead to questions regarding the ef-94 
ficacy of monotherapy with LT4 for all patients.3,7 We now know objectively that in LT4-treated 95 
patients that exhibit a normal serum TSH there is a 15-20% decrease in the ratio of circulating 96 
T3/T48; and about 15% of these patients do not maintain normal serum T3 levels.9 This is hy-97 
pothesized to be the result of differences in D2 regulation between the hypothalamus and periph-98 
eral tissues, as has been shown in a hypothyroid rat model.10 That replacement with LT4 does not 99 
fully restore all aspects of euthyroidism is supported by the observation that females taking LT4 100 
have lower energy expenditure compared to euthyroid women with similar age and body mass 101 
index.11 In addition, NHANES data indicate that individuals taking LT4, with TSH values within 102 
the normal reference range, have a higher BMI despite reporting lower calorie intake corrected 103 
by body weight, report lower physical activity levels, and are more often taking statins, beta-104 
blockers, and antidepressants compared to euthyroid participants matched by age, gender and 105 
race/ethnicity.8 They also report increased frequency of episodes of memory problems/confusion 106 
and are less likely to report being in excellent/good health.12  107 
 108 
Few physicians are willing to prescribe combination LT4 plus liothyronine (LT3) to manage re-109 
sidual symptoms;13 and minimal information is available to describe prescription patterns of  110 
desiccated thyroid extract (DTE, a porcine-derived thyroid hormone replacement containing both 111 
T4 and T3). However, it is not clear that combination therapy is superior to monotherapy in 112 
managing hypothyroidism. A total of 14 double blind placebo controlled trials provided hetero-113 
geneous results with respect to health-related quality of life and mood and neurocognitive func-114 
tioning; but there was a patient preference for combination therapy in some of the trials.6,14-26 In 115 
an attempt to query patients, a Danish internet-based questionnaire surveyed 293 individuals on 116 
combination therapy, revealing that 84% of patients who had residual symptoms while on mono-117 
therapy perceived improved symptoms after switching to combination therapy and 81% stated a 118 
clear preference for continuing combination therapy.27  119 
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 120 
The objective of the current study is to analyze the results of an online survey conducted in the 121 
spring of 2017 which assessed perceptions of hypothyroid patients regarding treatment effective-122 
ness and their satisfaction with physicians. Approximately 12,000 individuals taking LT4 mono-123 
therapy, combination therapy with LT4 and LT3, or desiccated thyroid extract, completed the 124 
survey which was posted on the American Thyroid Association (ATA)’s web site.  125 
 126 
MATERIALS AND METHODS 127 
 128 
Study participants 129 
A convenience sample of hypothyroid individuals was solicited to participate in an online Eng-130 
lish language survey to determine their perceptions regarding the treatment that they received for 131 
hypothyroidism. Participants were asked to report which thyroid hormone they were currently 132 
taking for treatment of hypothyroidism, demographic characteristics, etiology and duration of 133 
hypothyroidism, and concomitant medical conditions. 134 
 135 
Survey Development and Distribution 136 
The Hypothyroidism Treatment Survey was created by the program committee members of the 137 
Satellite Symposium on Hypothyroidism organized by the ATA that occurred in the Spring of 138 
2017 in Orlando FL. The program committee members deemed it important to describe the pa-139 
tient perspective regarding hypothyroidism treatment and share the results with program regis-140 
trants. The survey questions were created to identify demographic and treatment characteristics 141 
of individuals being treated for hypothyroidism, coupled with information about their satisfaction 142 
with their therapy.  143 
 144 
Participants were asked to provide their gender, age (categorized as under 40, 41-50 years old, 145 
51-60 years old, 61-70 years old, or over 70 years old), cause of their hypothyroidism (catego-146 
rized as Hashimoto’s/autoimmune disease, surgery/removal of thyroid, radioactive iodine (RAI) 147 
for overactive thyroid, I do not know, or other), and duration of hypothyroidism treatment (cate-148 
gorized as less than one year, 1-5 years, 6-10 years, more than 10 years). To recognize confound-149 
ing conditions that may contribute to symptoms overlapping with those of hypothyroidism, par-150 
ticipants were asked if stress or other medical problems could be contributing to their symptoms 151 
and were asked to identify any relevant medical problems that they had (including heart disease, 152 
lung disease, diabetes, bone or muscle disease, gastrointestinal disease, cancer (that is not thyroid 153 
cancer), thyroid cancer, and depression). 154 
 155 
Treatment was defined as taking a thyroid hormone for hypothyroidism; individuals were asked 156 
to select the type of thyroid hormone they were taking (categorized as levothyroxine, [including 157 
generic or branded forms of levothyroxine], levothyroxine and LT3 [liothyronine, Cytomel], nat-158 
ural thyroid or desiccated thyroid extract [Armour Thyroid, Nature-Throid], I do not know, or 159 
other [with the option to specify the thyroid hormone treatment]). The three treatments subjected 160 
to further analysis were levothyroxine (LT4), levothyroxine and LT3 (LT4+LT3), and desiccated 161 
thyroid extract (DTE).  Perception regarding treatment was examined by asking participants to 162 
rank, on a scale of 1 to 10,  their satisfaction with treatment and with the current physician treat-163 
ing their hypothyroidism (1=not satisfied, 10=completely satisfied), the perceived knowledge of 164 
their physician about treatment of hypothyroidism (1=not at all knowledgeable, 10=very knowl-165 
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edgeable), their assessment of the need for new treatments for hypothyroidism (1=no need, 166 
10=strong need), and the impact of hypothyroidism on their life (1=not affected, 10=strongly af-167 
fected). In addition to reporting the median, 25th, and 75th percentile of the responses, the distri-168 
bution of the responses was also presented in graphic form. Additional questions were added to 169 
assess participant’s experiences with their medical care for hypothyroidism; respondents were 170 
asked to categorize the number of times they changed physician because they were not satisfied 171 
with their hypothyroidism treatment (categorized as none, 1 time, 2-4 times, 5-9 times, or 10 or 172 
more times), identify relevant aspects of their life affected by hypothyroidism/thyroid hormone 173 
treatment (categorized as weight management, fatigue or energy levels, mood, and memory or 174 
other problems with thinking), and prevalence of seeking alternative form of hypothyroidism 175 
treatment, not prescribed by your doctor (yes/no).  176 
 177 
The survey (available in the Supplemental Materials and Methods) was available online from 178 
1/28/2017 to 3/30/2017. A link to the survey was posted on the ATA website and distributed via 179 
email to patients within the ATA database and to the members of the ATA Alliance for Thyroid 180 
Patient Education. Members of the ATA were encouraged to further distribute the survey by 181 
sharing on group websites and social media. Additionally, the link was included in the Signal 182 
eNews, a monthly newsletter emailed to ATA members. No identifying or protected health in-183 
formation was collected from participants. Only IP address was recorded for the purpose of elim-184 
inating duplicate responses. 185 
 186 
Initial analysis was conducted on the total sample (comprised of respondents taking LT4, LT4 + 187 
LT3, or DTE). In addition, four subgroups were created based on disease characteristics in order 188 
to further analyze perceptions regarding treatment of hypothyroidism according to the 3 treat-189 
ments. These groups were as follows: Subgroup-1: respondents without self-reported depres-190 
sion, stress or medical conditions; Subgroup-2: due to difference in age, gender, and hypothy-191 
roid treatment between respondents taking LT4, LT4 + LT3, and DTE a matched subgroup of 192 
females was created - those taking LT4 and DTE (the tw largest groups of respondents) were 193 
matched 2:1 by age, hypothyroidism treatment, etiology of hypothyroidism, and treatment dura-194 
tion to individuals taking LT4+LT3 (the smallest group of respondents) to account for baseline 195 
differences; Subgroup-3: respondents with depression but no reported life-stressors or medical 196 
conditions; and Subgroup-4: respondents with thyroid cancer but no self-reported depression, 197 
life-stressors or medical condition. 198 
 199 
Statistical methods 200 
Analyses were completed with IBM SPSS Statistics (version 22.0). Both frequency (percent) and 201 
median (interquartile range [25th, 75th percentile]) were used to describe the data.  The Kruskal 202 
Wallis test was used to compare difference in ranked median perception across the three medica-203 
tion treatment groups (LT4 vs LT4+LT3 vs DTE). If a significant difference was observed, the 204 
Mann-Whitney U test was used to perform between group analyses. The chi-square test of asso-205 
ciation was utilized to determine difference in categorical variables across the three medication 206 
treatment groups (LT4 vs LT4+LT3 vs DTE). Due to the multiple comparisons performed, a 207 
conservative p value of <0.001 was utilized to identify statistically significant differences be-208 
tween groups. This rigorous p value was chosen in order to avoid over-interpreting results in the 209 
setting of a survey-based dataset. 210 
 211 
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RESULTS 212 
 213 
A total of 12,146 respondents completed the survey and all subsequent analyses were performed 214 
based on the self-reported responses to questions about medical history and hypothyroidism 215 
treatment. We excluded 53 respondents that were not taking medication for hypothyroidism. Of 216 
the remaining 12,093 individuals (Supplement Table 1), 485 were excluded because they were 217 
taking a medication for hypothyroidism other than LT4, LT4 + LT3, or DTE. An additional 442 218 
were excluded due to survey completion from the same IP address and concern that the data rep-219 
resented duplicate surveys. As a result, the total sample of respondents that was further analyzed 220 
comprised 11,166 individuals (Figure 1).  221 
 222 
The female/male ratio of respondents was approximately 21:1 and age was relatively evenly dis-223 
tributed across the four age categories (Table 1). The most prevalent cause of hypothyroidism 224 
was Hashimoto’s/autoimmune disease (43%); however, 34% of respondents identified another 225 
cause other than Hashimoto’s/RAI/surgery or were unsure of hypothyroidism etiology (Table 1).  226 
Only 7% of individuals were treated for hypothyroidism for less than one year; the majority 227 
(63%) had been on treatment for more than 6 years. One-third of patients stated that their current 228 
stress level could be contributing to hypothyroid-related symptoms; another third reported co-229 
existing medical conditions, with the most common one being depression (27%). Only 6% of 230 
respondents self-reported depression without any other comorbidities (Table 1). 231 
 232 
Within the total sample, 6,949 individuals were taking LT4 monotherapy, 978 reported taking 233 
combination LT4+LT3, and 3,239 received DTE (Table 1). When considering perceptions re-234 
garding their treatment for hypothyroidism, the median response indicating treatment satisfaction 235 
was 5 (25th-75th percentile interval: 3, 8) (Table 1). Among those who were frustrated with their 236 
hypothyroidism treatment, the relevant areas identified as causing dissatisfaction were weight 237 
management (69%), fatigue or energy level (77%), mood (45%), and memory or other problems 238 
thinking (58%). The median response describing satisfaction with the patient’s current physician 239 
was 6 (25th-75th percentile interval: 3,6) and assessment of the doctor/physician knowledge re-240 
garding hypothyroidism treatment was 5 (25th-75th percentile interval: 3, 8); 54% of the sample 241 
reported changing physicians more than twice because of dissatisfaction with treatment. Almost 242 
all respondents believed that there was a strong need for new treatments for hypothyroidism 243 
(median 10 (25th-75th percentile interval: 8,10)) and perceived a significant influence of hypothy-244 
roidism on life (median 10 (25th-75th percentile interval: 8,10)) (Table 1).    245 
 246 
Next, multiple analyses were utilized to compare the responses within the total sample according 247 
to their specific treatment (Table 2). When examining the three treatment sub-groups, the distri-248 
bution of gender, age, etiology and treatment duration were significantly different.  Individuals 249 
treated with DTE had the highest median satisfaction with treatment (7 (25th-75th percentile in-250 
terval: 4,8)) compared to those taking LT4 (5 (25th-75th percentile interval: 3,7)) or LT4+LT3 (5 251 
(25th-75th percentile interval: 3,7)). In particular, as shown in the graphic representations, the dis-252 
tribution of responses was markedly different between those taking DTE versus LT4 (Table 2); 253 
individuals on DTE predominately responded positively with an upward trend, such that re-254 
sponses were more frequent at the positive end of the scale. Conversely, individuals on LT4 were 255 
more likely to respond negatively, exhibiting a distribution with a downward trend, such that re-256 
sponses were more frequent at the negative end of the scale (Table 2). This varied distribution 257 
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between groups can also described by examining the number of patients who ranked satisfaction 258 
with treatment as not satisfied (ranked 1 or 2) or completely satisfied (ranked 9 or 10); approxi-259 
mately 20% of respondents taking LT4 and LT4+LT3 were not satisfied with treatment while 260 
14% of DTE users were not satisfied. In comparison, 22% of DTE users were completely satis-261 
fied compared to 10% of LT4 and LT4+LT3 respondents (Supplementary Figure 1).  Individuals 262 
taking DTE were less likely to report problems with weight management, fatigue/energy level, 263 
mood, or memory when compared to those taking LT4 or LT4+LT3 (Table 2). Individuals taking 264 
DTE had a higher median satisfaction with their current physician (7 (25th-75th percentile inter-265 
val: 4,9)) compared to those taking LT4 (5 (25th-75th percentile interval: 3,8)) or LT4+LT3 (6 266 
(25th-75th percentile interval: 3-8)); perceived physician knowledge was slightly higher in the 267 
DTE subgroup, compared with the LT4 subgroup (Supplementary Figure 2 and 3). Of note, 29% 268 
and 21% of individuals taking DTE and LT4+LT3 changed doctors ≥ 5 times because they were 269 
not satisfied with their treatment, compared to only 7% of respondents taking LT4. Those taking 270 
DTE or LT4+LT3 were more likely to have tried alternative treatment forms not prescribed by 271 
their doctor and thought their lives had been more affected by hypothyroidism (10 (25th-75th per-272 
centile interval: 9-10)), although this latter parameter was very high in all three subgroups (Table 273 
2 and Supplementary Table 4). 274 
 275 
Analyses of Subgroups-1-4 276 
 277 
Subgroup-1 (Supplement Table 2, n=3,670) captures respondents without self-reported depres-278 
sion, life-stressors or medical conditions. Those taking LT4 had a median reported treatment sat-279 
isfaction of 5 (25th-75th percentile interval: 3,7) (Table 3). Their perception regarding treatment 280 
of hypothyroidism were as follows: physician satisfaction of 5 (25th-75th percentile interval: 3,8) 281 
and physician knowledge of 5 (25th-75th percentile interval: 3,8). Individuals taking combination 282 
therapy with LT4+LT3 experienced slightly higher treatment satisfaction (6 (25th-75th percentile 283 
interval: 3,8), with similar physician satisfaction and perceived physician knowledge. Respond-284 
ents taking DTE had the highest scores in treatment satisfaction (7 (25th-75th percentile interval: 285 
5,9)) and physician satisfaction (7 (25th-75th percentile interval: 4,9)). Regardless of treatment 286 
modality, all respondents ranked at the highest level (9-10) the need for new treatments and the 287 
perception of how much their lives had been affected by hypothyroidism (Table 3).  Additional-288 
ly, respondents taking DTE were less likely to report weight management concerns, fatigue/low 289 
energy levels, mood issues, or memory problems compared to those on LT4 or LT4+LT3 (Table 290 
4). 291 
 292 
Subgroup-2 (Supplement Table 3, n=1535) is a matched subset of Subgroup-1 with the re-293 
spondents taking LT4 and DTE being matched 2:1 by gender (only female respondents), age, 294 
etiology of hypothyroidism, and treatment duration to individuals taking LT4+LT3. The match-295 
ing resulted in the size of the groups being reduced to 1535 respondents (Table 3). Despite the 296 
matching, the results obtained in Subgroup-2 remained very similar to Subgroup-1 (Table 3 and 297 
Table 4).    298 
 299 
Subgroup-3 (Supplement Table 4, n=679) respondents, who reported depression, but did not 300 
report stressors or other medical conditions, in general ranked lower on all parameters when 301 
compared to other subgroups. The median perception of those taking LT4 regarding treatment 302 
satisfaction was 4 (25th-75th percentile interval: 1,6), physician satisfaction was 5 (25th-75th per-303 
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centile interval: 2,7) and physician knowledge was 4 (25th-75th percentile interval: 2,6) (Table 3). 304 
Individuals on LT4+LT3 reported similar perceptions (Table 3). Respondents taking DTE had 305 
the highest scores for: treatment satisfaction 5 (25th-75th percentile interval: 3,7)) and physician 306 
satisfaction 6 (25th-75th percentile interval: 3,8), albeit lower than Subgroups 1-2. Perception of 307 
physician knowledge remained low (4 (25th-75th percentile interval: 2,8)), similar to other treat-308 
ment groups. Respondents using all treatment modalities ranked at the highest level (10) the need 309 
for new treatments and the perception of how much their lives had been affected by hypothyroid-310 
ism (Table 3). Within this group, respondents taking DTE were less likely to report fatigue/low 311 
energy levels and memory problems compared to those on LT4 or LT4+LT3, though the differ-312 
ence did not reach the statistical significance criterion of p<0.001 (Table 4). 313 
 314 
Subgroup-4 (Supplement Table 5, n=346) respondents (those with thyroid cancer, but no other 315 
reported co-morbidities) exhibited a similar upward trend in treatment satisfaction with DTE, 316 
although not reaching statistical significance (Table 3); perceptions about physician satisfaction 317 
also did not exhibit statistical significance between treatments. Notably, physician knowledge 318 
exhibited a downward trend, with patients on DTE ranking the lowest (4 (25th-75th percentile in-319 
terval: 3,7). As before, the need for new treatments and impact of hypothyroidism on their lives 320 
were ranked at the highest level (Table 3). Within this group, there was a trend toward respond-321 
ents taking LT4+LT3 being more likely to report weight management as a relevant area affected 322 
by hypothyroidism compared to LT4 users. There was a trend towards those taking DTE being 323 
less likely to report fatigue/low energy levels and mood issues compared to those on LT4 or 324 
LT4+LT3 (Table 4). Respondents taking DTE exhibited a trend towards being less likely to re-325 
port memory problems compared to LT4+LT3 users (Table 4). 326 
 327 
DISCUSSION 328 
 329 
The present study reports the results of a large-scale assessment of patients’ perceptions about 330 
hypothyroidism. The results suggest that dissatisfaction with hypothyroidism treatment and treat-331 
ing physicians are important problems for patients. Furthermore, a strong need for development 332 
of new treatments for hypothyroidism was identified. These are dramatic findings, as among 333 
physicians treatment of hypothyroidism is considered to be straightforward. The fact that the 334 
median reported satisfaction with treatment in the entire group is only 5 on a scale of 1-10 is re-335 
markable, and even if this only reflects the situation in a small portion of patients, this is very 336 
concerning. Given that hypothyroidism is a common disease, this could translate into a signifi-337 
cant burden of unsuccessfully resolved symptoms within the entire population. At face value, 338 
these results indicate that, although physicians believe that hypothyroidism is an eminently treat-339 
able condition, a large number of hypothyroid patients believe their lives have been greatly af-340 
fected by the disease, are profoundly unhappy with their treatment, and are unhappy with their 341 
physicians. Almost universally, they believe there is a need for the development of new treat-342 
ment forms. It is also remarkable that there is a clear preference for DTE in the whole group as 343 
well as when the group was broken down in multiple subgroups. Of course, the study is limited 344 
by the potential intrinsic sample bias. However, the suggestion that something “real” is being 345 
captured is bolstered by the finding that our survey did not demonstrate a clear positive patient 346 
response to synthetic combination therapy with LT4+LT3. 347 
 348 
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The present study is based on responses provided by a convenience sample that is unlikely to 349 
represent the more than 10 million Americans being treated for hypothyroidism. For example, it 350 
is likely that there is selection bias, with underrepresentation of LT4-treated patients that are not 351 
symptomatic who are less likely to be reached by thyroid-related social media. However, these 352 
results corroborate recent findings obtained from NHANES data, a population-based survey rep-353 
resentative of individuals within the United States (a computer algorithm randomly selects 354 
households from representative regions throughout the country). Notably, the NHANES LT4-355 
treated individuals struggled with the very same issues identified by the current sample, i.e. 356 
weight management, low energy levels, depression and poor cognition compared to age, gender 357 
and race/ethnicity matched euthyroid controls.8,12 These differences, however, were not signifi-358 
cantly associated with serum T3 levels, again highlighting the need to gain a better understand-359 
ing of underlying mechanisms. 360 
 361 
The focus of prior research into combination therapy has been using synthetic LT4+LT3, rather 362 
than DTE. The fourteen trials of synthetic LT4+LT3 that have been completed thus far show 363 
some patient preference for combination therapy, but have failed to show obvious superiority of 364 
LT4+LT3.6,14-20,22-26,28  Thyroid-related symptoms were generally not improved with combina-365 
tion therapy, other than when TSH suppression was achieved. Parameters such as quality of life, 366 
mood, and neurocognitive performance were only improved in a minority of studies. These stud-367 
ies have multiple limitations (e.g. once daily dosing, short duration study, small study size, dis-368 
parate TSH values between study groups) that have been previously reviewed extensively.2,29 369 
Failure to demonstrate superiority of LT4+LT3 could be due to any combination of these short-370 
comings in study design or the drug formulation. However, it is also possible that synthetic com-371 
bination therapy is simply not superior to LT4. The one double blind, randomized, placebo con-372 
trolled trial of DTE versus LT4 also failed to show that DTE resulted in improvement in a num-373 
ber of neuropsychological measures.28 There was a preference for DTE, which was associated 374 
with the very modest, short-term weight loss of 3lbs that was associated with DTE. However, 375 
long-term, outcome data were not reported, and it is not known if the weight loss was sustained. 376 
A preference for LT4+LT3 has also been shown to be associated with the weight loss achieved 377 
during therapy, although TSH suppression was a confounding factor.14 378 
 379 
If the clinical trials conducted up to now have not shown benefits of either LT4+LT3 or DTE, 380 
but uncontrolled patients surveys27 or online patient forum opinions suggest that combination 381 
therapy is preferred, this could simply reflect biased data, or it is also possible that the appropri-382 
ate patient group has not yet been formally studied. Prospective clinical trials of combination 383 
therapy have not yet been conducted that have specifically recruited dissatisfied patients, patients 384 
with the lowest circulating T3 levels; few trials have considered deiodinases or thyroid hormone 385 
transporters polymorphisms. Certainly, retrospective data suggest that patient preference may be 386 
linked to a patients’ complement of thyroid hormone metabolism-associated polymorphisms.30,31  387 
 388 
If DTE actually does provide more satisfactory therapy for patients with hypothyroidism, it is 389 
possible that this is due to (i) patient preference for higher treatment doses ii) patients being ren-390 
dered T3-thyrotoxic, (iii) the presence of some other orally active substance other than T4 and 391 
T3 within the DTE, or (iv) a confounding factor such as use of other complementary or alterna-392 
tive medicine in users of DTE, or (v) an as yet unidentified aspect of thyroid physiology. It is 393 
important to keep in mind though that DTE, like LT4, does not restore normal thyroid hormone 394 
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homeostasis. Circulating levels of T3 are increased during DTE therapy and may transiently ex-395 
ceed the upper limits of normal, while the average blood levels of T4 are below the lower limit 396 
of normal. High levels of T3 are known to enhance mood in studies of patients with depression 397 
and it is possible that patient preference for DTE reflects a positive effect of supra-physiologic 398 
T3 levels on mood. At the same time, it is unknown whether transient supra-physiologic T3 lev-399 
els are safe or whether they could promote arrhythmias, especially in older or susceptible pa-400 
tients. With respect to patients potentially preferring higher doses, it has recently been shown in 401 
a randomized blinded trial that patients preferred the LT4 dose that they believed was the highest 402 
dose, even if they had not identified the relative dose correctly.32 403 
 404 
A major strength of this study is the large sample size. However limitations of the study include 405 
probable sampling and/or recall bias, subjectivity, a lack of an external control (e.g. patients 406 
treated for other endocrine disorders or other chronic medical conditions), and the use of an non-407 
validated survey instrument. With respect to the first limitation, we acknowledge the increased 408 
likelihood that patients with significant dissatisfaction with their therapy for hypothyroidism are 409 
more likely to have been motivated to complete the survey than those who feel unaffected by 410 
their hypothyroidism, or even those who feel very happy about their treatment. To highlight this 411 
50% of our survey respondents had changed their physician twice or more. It is anticipated, alt-412 
hough not verified, that this questionnaire attracted dissatisfied patients or was preferentially 413 
publicized among groups of dissatisfied patients. We therefore anticipate that we have captured 414 
one, or possibly both, ends of the spectrum of opinion about treatment. If we assume that approx-415 
imately 15% of treated patients feel worse than individuals without thyroid disease, and if we 416 
have captured a subset of these patients, our results, despite the inherent bias, nevertheless indi-417 
cate a significant unmet need among patients. We also seem to have captured predominately fe-418 
males in our survey. We know that hypothyroidism affects women/men with a ratio of 9:1, and 419 
yet our respondents exhibited a ratio of 21:1.  420 
 421 
With respect to the third and fourth limitations, because the diagnosis of hypothyroidism is self-422 
reported, we cannot be sure that the respondents do not include a significant number of individu-423 
als who are taking thyroid hormone because of a misdiagnosis of hypothyroidism or for a condi-424 
tion other than hypothyroidism, for example fibromyalgia . Additionally, hypothyroid patients 425 
may also mistakenly attribute unrelated symptoms or decreased quality of life to their thyroid 426 
condition. Once a patient has been diagnosed with a chronic condition such as hypothyroidism, 427 
there is a natural tendency for a patient to associate their spectrum of symptoms with this condi-428 
tion. The attribution of these symptoms may be mistaken. If there is mis-attribution of symp-429 
toms, then these symptoms would not be expected to resolve with adjustment of therapy for hy-430 
pothyroidism. It is well known that patients with hypothyroidism have a greater disease burden 431 
than the general population6,33, and that hypothyroid patients treated to achieve a normal TSH 432 
remain symptomatic.34,35 However, not only does manipulation of thyroid status in these individ-433 
uals fail to resolve symptoms,25,32 but also treatment of euthyroid individuals with hypothyroid-434 
like symptoms does not resolve symptoms.36 We attempted to mitigate these particular limita-435 
tions by requesting that respondents report co-existent medical conditions and examining sub-436 
groups who did not have these conditions. In general, our findings remained generally unaltered 437 
in these subgroup analyses. However, we do not know if we have fully captured other medical 438 
conditions that might be the major source of some of the symptoms reported. 439 
 440 
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In conclusion, it is clear that a subset of patients with hypothyroidism are not satisfied with their 441 
current therapy, nor their physicians. This is unexpected. These findings highlight the need for 442 
high quality research to study treatments for hypothyroidism. Such treatments may include hor-443 
monal therapies, supportive care interventions, lifestyle modification interventions (e.g. exercise, 444 
diet), or complementary/alternative treatments. Definitive trials need to be adequately statistical-445 
ly powered to detect clinically significant changes in important patient outcomes, attempt to pro-446 
vide steady levels of T3, and specifically target individuals who are symptomatic. Failure to con-447 
duct well-designed studies to advance our understanding in this area promotes reliance on anec-448 
dotal case reports/series, self-report survey studies (such as this one), and observational registry 449 
data. In the absence of a better understanding of hypothyroidism treatment patients will continue 450 
to experience unresolved symptoms and be exposed to the risks and expenses of treatments with 451 
unproven benefits and possible harm.37  452 
 453 
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Table 1: Demographic data, hypothyroid disease characteristics and perceptions regarding hypothyroid treat-
ment for the total sample (n=11,166) 
Survey section Survey question Possible response Respondents 
Demographics 
Gender* Female Male 
10664 (96%) 
502 (4%) 
Age*       
31-40 years 
41-50 years 
51-60 years 
≥61 years 
2464 (22%) 
3217 (29%) 
2830 (25%) 
2655 (23%) 
Hypothyroid 
etiology and 
treatment 
Etiology of hypothyroidism*                                
Hashimoto/autoimmune 
Radioactive iodine 
Surgery 
Other/Not known 
4812 (43%) 
858 (8%) 
1694 (15%) 
3802 (34%) 
What thyroid hormone are you 
currently taking? * 
LT4 
LT4 + LT3 
DTE 
6949 (62%) 
978 (9%) 
3239 (29%) 
Hypothyroid treatment dura-
tion*                         
Less than 1 year 
1-5 years 
6-10 years 
More than 10 years 
814 (7%) 
3337 (30%) 
2486 (22%) 
4529 (41%) 
Self-reported 
medical history 
Is a condition not related to 
thyroid hormone causing your 
symptoms? 
Current stress levels 
Other medical problem 
No condition identified 
3727 (33%) 
3578 (32%) 
3,861 (34%) 
Do you have any of these med-
ical problems? 
Heart disease 
Lung disease 
Diabetes 
Bone/Muscle disease 
GI disease 
Cancer (non-thyroid) 
Depression 
510 (5%) 
312 (3%) 
681 (6%) 
868 (8%) 
1506 (14%) 
243 (2%) 
2965 (27%) 
Perception  
regarding  
hypothyroid 
treatment 
How satisfied are you with the 
treatment you receive? + 
1= not satisfied 
10=very satisfied 5 (3,8) 
 
If you are not satisfied, indi-
cate relevant areas you feel are 
affected by your thyroid treat-
ment 
Weight management 7729 (69%) 
Fatigue or energy levels 8597 (77%) 
Mood 5059 (45%) 
Memory 6433 (58%) 
How satisfied are you with 
your current physician who 
treats you for your thyroid 
condition? + 
1= not satisfied 
10=very satisfied 6 (3,8) 
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Table 1, continued 
 
How knowledgeable is your 
doctor and/or physicians in 
general about hypothyroid 
treatment? + 
1=not knowledgeable 
10= very knowledgeable 5 (3,8) 
 
How many times have you 
changed doctors because you 
were not satisfied with the 
treatment you were receiving? 
*
                                                       
Never 
1 time 
2-4 times 
5-9 times 
More than 10 
3185 (29%) 
1944 (17%) 
4375 (39%) 
1349 (12%) 
313 (3%) 
How would you rate the need 
for new treatments for hypo-
thyroidism? + 
1=no need 
10=strong need 10 (8,10) 
 
Tried alternative hypothyroid 
treatment not prescribed by 
doctor 
Yes 3108 (28%) 
No 8058 (71%) 
How has your life been affect-
ed by your hypothyroidism? + 
1=not affected 
10=strongly affected 10 (8,10) 
 
* Summarized as frequency (percent)                                 
+ Summarized as median  (25th percentile, 75th percentile) 
 568 
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Table 2: Comparison of demographic data, characteristics of hypothyroidism and perceptions regarding hypothyroidism treatment by self-reported 
medication (LT4, LT4+LT3 or DTE) for the total sample (n=11,166) 
Survey question Possible response LT4  (n=6949) LT4+LT3  (n=978) DTE  (n=3239) p-value 
Gender* Female Male 
6546 (94%) 
403 (6%) 
944 (97%) 
34 (3%) 
3174 (98%) 
65 (2%) <0.0001 
Age*       
31-40 years 
41-50 years 
51-60 years 
≥61 years 
1553 (22%) 
1857 (27%) 
1709 (25%) 
1830 (26%) 
230 (23%) 
286 (29%) 
258 (27%) 
204 (21%) 
681 (21%) 
1074 (33%) 
863 (27%) 
621 (20%) 
<0.0001 
Etiology of  
hypothyroidism*                                    
Hashimoto/autoimmune 
Radioactive iodine 
Surgery 
Other 
2587 (37%) 
629 (9%) 
1149 (17%) 
2587 (38%) 
475 (49%) 
67 (7%) 
185 (19%) 
251 (12%) 
1750 (54%) 
162 (5%) 
360 (12%) 
967 (30%) 
<0.0001 
Hypothyroid treatment  
duration*                         
Less than 1 year 
1-5 years 
6-10 years 
More than 10 years 
609 (9%) 
2012 (29%) 
1507 (22%) 
2821 (41%) 
32 (3%) 
268 (27%) 
245 (25%) 
433 (44%) 
173 (5%) 
1057 (33%) 
734 (23%) 
1275 (39%) 
<0.0001 
Is a condition not related to 
thyroid hormone causing 
your symptoms? 
     
Do you have any of these 
medical problems?      
How satisfied are you with 
the treatment you receive? + 
1= not satisfied 
10=very satisfied 
5 (3, 7) 5 (3,7) 7 (4,8)^ # 
<0.0001 
   
If you are not satisfied, in-
dicate relevant areas you 
feel are affected by your 
thyroid treatment*          
Weight management 4889 (70%) 704 (72%) 2136 (65%) <0.0001 
Fatigue or energy levels 5547 (80%) 793 (81%) 2257 (70%) <0.0001 
Mood 3369 (49%) 458 (47%) 1232 (38%) <0.0001 
Memory 4150 (60%) 612 (63%) 1671 (52%) <0.0001 
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How satisfied are you with 
your current physician who 
treats you for your thyroid 
condition? + 
1= not satisfied 
10=very satisfied 
5 (3,8) 
 
6 (3,8) 
 
7 (4,9) ^# 
 
<0.0001 
Table 2, continued 
How knowledgeable is your 
doctor and/or physicians in 
general about hypothyroid 
treatment? + 
1=not knowledgeable 
10= very knowledgeable 
5 (3,8) 5 (3,8) 5 (2,8)  
0.012 
 
 
 
How many times have you 
changed doctors because 
you were not satisfied with 
the treatment you were  
receiving? *                                           
Never 
1 time 
2-4 times 
5-9 times 
More than 10 
2775 (39%) 
1476 (21%) 
2408 (33%) 
456 (6%) 
92 (1%) 
163 (16%) 
156 (15%) 
481 (48%) 
176 (17%) 
37 (4%) 
372 (11%) 
407 (12%) 
1636 (48%) 
783 (23%) 
190 (6%) 
<0.0001 
How would you rate the 
need for new hypothyroid 
treatments? + 
1=no need 
10=strong need 
10 (8,10) 10 (9,10) ^ 10 (10,10) ^ 
<0.0001 
 
  
Tried alternative hypothy-
roid treatment not pre-
scribed by doctor* 
Yes 1316 (19%) 309 (32%) 1483 (46%) 
<0.0001 
No 5633 (81%) 669 (68%) 1756 (54%) 
How has your life been af- 1=not affected 9 (7,10) 10 (8,10) ^ 10 (9,10) ^ <0.0001 
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569 
fected by your  
hypothyroidism? + 
10=strongly affected 
   
* Summarized as frequency (percent)                                      
+ Summarized as median  (25th percentile, 75th percentile), differences between groups determined by Kruskal-Wallis test 
^
 Significantly different from respondents taking LT4 by Mann Whitney U test (p<0.0001)       
# Significantly different from respondents taking LT4+T3 by Mann Whitney U test (p<0.0001)                           
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Table 3: Comparison median perception of satisfaction regarding hypothyroid treatment by  
self-reported medication. 
SUBGROUP-1: Respondents without depression,  stress-
ors, or medical conditions  
 
LT4 
(n=2206) 
LT4 +LT3 
(n=316) 
DTE 
(n=1148) p-value 
How satisfied are you with the treatment you receive?  5 (3,7) 6 (3,8) 7 (5,9) ^# <0.0001 
How satisfied are you with your current physician who 
treats you for your thyroid condition?  5 (3,8) 6 (3,8) 7 (4,9) 
^
 <0.0001 
How knowledgeable is your doctor and/or physicians in 
general about hypothyroid treatment?  5 (3,8) 5 (3,8) 5 (2,8) 
0.04 
How would you rate the need for new hypothyroid treat-
ments?  10 (8,10) 10 (10,10)
^
 10 (10,10) ^ <0.0001 
How has your life been affected by your hypothyroidism?  9 (7,10) 10 (9,10)^ 10 (8,10) ^ <0.0001 
 
SUBGROUP-2: Respondents without depression,  stress-
ors, or medical condition matched by gender, age & hypo-
thyroid treatment 
 
LT4 
(n=614) 
LT4 +LT3  
(n=307) 
DTE 
 (n=614) p-value 
How satisfied are you with the treatment you receive?  5 (3,7) 6 (3,8) 7 (5,9) ^# <0.0001 
How satisfied are you with your current physician who 
treats you for your thyroid condition?  5 (3,8) 6 (3,8) 
^
 7 (3,9) ^ <0.0001 
How knowledgeable is your doctor and/or physicians in 
general about hypothyroid treatment?  5 (2,7) 5 (3,8) 5 (2,8) 0.05 
How would you rate the need for new hypothyroid treat-
ments?  10 (8,10) 10 (10,10) 
^
 10 (10,10) ^ <0.0001 
How has your life been affected by your hypothyroidism?  9 (7,10) 10 (8,10) 10 (8,10) <0.0001 
 
SUBGROUP-3: Respondents with depression, but without 
stressors or medical conditions 
 
LT4 
(n=457) 
LT4 +LT3 
(n=42) 
DTE 
(n=180) p-value 
How satisfied are you with the treatment you receive?  4 (1,6) 4 (2,6) 5 (3,7)^ <0.0001 
How satisfied are you with your current physician who 
treats you for your thyroid condition?  5 (2,7) 5 (2,8) 6 (3,8)
 ^
 0.001 
How knowledgeable is your doctor and/or physicians in 
general about hypothyroid treatment?  4 (2,6) 5 (2,7) 4 (2,8) 0.824 
How would you rate the need for new hypothyroid treat-
ments?  10 (9,10) 10 (10,10)
 
 10 (10,10) ^ <0.0001 
How has your life been affected by your hypothyroidism?  10 (8,10) 10 (10,10)  10 (10,10) ^ <0.0001 
 
SUBGROUP-4: Thyroid cancer without depression,  
stressors, or medical conditions  
 
LT4 
(n=224) 
LT4 +LT3 
(n=48) 
DTE 
 (n=74) p-value 
How satisfied are you with the treatment you receive?  5 (3,8) 6 (4,8) 7 (3,8)  0.224 
How satisfied are you with your current physician who 
treats you for your thyroid condition?  7 (4,8) 6 (3,9) 6 (2,8) 0.117 
How knowledgeable is your doctor and/or physicians in 
general about hypothyroid treatment?  7 (4,9) 6 (4,9) 4 (3,7)
 ^
 <0.0001 
How would you rate the need for new hypothyroid treat-
ments?  10 (7,10) 10 (10,10)
 
 10 (10,10)  <0.0001 
How has your life been affected by your hypothyroidism?  10 (8,10) 10 (10,10) ^ 10 (9,10)  <0.0001 
^
 Significantly different from respondents taking LT4 by Mann Whitney U test (p<0.0001)       
# Significantly different from respondents taking LT4+T3 by Mann Whitney U test (p<0.0001)                           
 570 
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Table 4: Comparison of hypothyroid side-effects that are a primary concern to respondents by self-
reported medication 
SUBGROUP-1: Respondents without depression,  stress-
ors, or medical conditions 
 
LT4 
(n=2206) 
LT4 +LT3 
(n=316) 
DTE 
(n=1148) p-value 
Weight management 69% 74% 64% # <0.0001 
Fatigue/energy levels 75% 76% 64% ^# <0.0001 
Mood 42% 40% 30% ^# <0.0001 
Memory or other problems with thinking 55% 59% 44% ^# <0.0001 
 
SUBGROUP-2: Respondents without depression,  stress-
ors, or medical condition matched by gender, age & hypo-
thyroid treatment 
 
LT4 
(n=614) 
LT4 +LT3  
(n=307) 
DTE 
 (n=614) p-value 
Weight management 71% 74% 59%^# <0.0001 
Fatigue/energy levels 81% 77% 62%^# <0.0001 
Mood 47% 40% 29%^# <0.0001 
Memory or other problems with thinking 62% 59% 43%^# <0.0001 
SUBGROUP-3: Respondents with depression, but without 
stressors or medical conditions 
 
LT4 
(n=457) 
LT4 +LT3 
(n=42) 
DTE 
(n=180) p-value 
Weight management 77% 71% 75% 0.690 
Fatigue/energy levels 87% 93% 77% 0.002 
Mood 64% 60% 58% 0.252 
Memory or other problems with thinking 74% 71% 61% 0.005 
SUBGROUP-4:Thyroid cancer without depression,  
stressors, or medical conditions 
 
LT4 
(n=224) 
LT4 +LT3 
(n=48) 
DTE 
 (n=74) p-value 
Weight management 59% 79% 64% 0.031 
Fatigue/energy levels 77% 85% 65% 0.026 
Mood 44% 50% 28% 0.028 
Memory or other problems with thinking 55% 65% 45% 0.087 
^
 Significantly different from respondents taking LT4 by Chi-square test (p<0.0001)       
# Significantly different from respondents taking LT4+T3 by Chi-square test (p<0.0001)                           
 571 
 572 
 573 
